Form 6-K Polyrizon Ltd. For: Oct 30
Polyrizon Ltd. - Ordinary Shares (PLRZ)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
PLRZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLRZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLRZ alerts
High impacting Polyrizon Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PLRZ
News
- Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Targetâ„¢ (T&T) Intranasal Drug Delivery PlatformGlobeNewswire
- Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical TrialGlobeNewswire
- Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal TechnologiesGlobeNewswire
- Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical AffairsGlobeNewswire
- Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy BlockerGlobeNewswire
PLRZ
Sec Filings
- 1/30/25 - Form 6-K
- 1/23/25 - Form 6-K
- 1/22/25 - Form S-8
- PLRZ's page on the SEC website